Möricke A - Search Results

1

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M; German-Austrian-Swiss ALL-BFM Study Group. Möricke A, et al. Blood. 2008 May 1;111(9):4477-89. doi: 10.1182/blood-2007-09-112920. Epub 2008 Feb 19. Blood. 2008. PMID: 18285545 Free article. Clinical Trial.

2

Absence of mutations in the CDKN2 binding site of CDK4 in childhood acute lymphoblastic leukemia.

Einsiedel HG, Taube T, Beyermann B, Dragon S, Möricke A, Kebelmann-Betzig C, Köchling J, Henze G, Seeger K. Einsiedel HG, et al. Among authors: moricke a. Leuk Lymphoma. 2001 Jan;40(3-4):413-7. doi: 10.3109/10428190109057941. Leuk Lymphoma. 2001. PMID: 11426564

3

The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia.

Meissner B, Stanulla M, Ludwig WD, Harbott J, Möricke A, Welte K, Schrappe M. Meissner B, et al. Among authors: moricke a. Leukemia. 2004 Nov;18(11):1920-3. doi: 10.1038/sj.leu.2403521. Leukemia. 2004. PMID: 15457183 No abstract available.

4

Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.

Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M. Möricke A, et al. Klin Padiatr. 2005 Nov-Dec;217(6):310-20. doi: 10.1055/s-2005-872515. Klin Padiatr. 2005. PMID: 16307416

5

Over 15 years of ELTEC: A report of the international BFM study group.

Paulides M, Haupt R, Jankovic M, Möricke A, Langer T, Beck JD; ELTEC GroupELTEC members: E. Frey, H. Lackner, A. Moser, Austria; R. Maurus, J. Otten, P. Philippet, Belgium; J.D. Beck, G. Calaminus, H.G. Dörr, T. Langer, A. Möricke, M. Paulides, T. Rau, Germany; M.M. Hawkins, A. Taylor, Great Britain; E. Magyarosy, Hungary; E. Castagnola, A. Colombini, F. Fioredda, R. Haupt (Chairman), M. Jankovic, C. Manganini (Secretary), C. Micalizzi, P. Reciputo, M.G. Valsecchi, Italy; J.P.M. Bökkerink, W. Tissing, The Netherlands; A. Feldges, J. Greiner, Swit. Paulides M, et al. Among authors: moricke a. Pediatr Blood Cancer. 2007 Jul;49(1):113-4; discussion 112. doi: 10.1002/pbc.21087. Pediatr Blood Cancer. 2007. PMID: 17066469 No abstract available.

6

Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.

Stanulla M, Cario G, Meissner B, Schrauder A, Möricke A, Riehm H, Schrappe M. Stanulla M, et al. Among authors: moricke a. Blood Cells Mol Dis. 2007 Sep-Oct;39(2):160-3. doi: 10.1016/j.bcmd.2007.04.005. Epub 2007 May 25. Blood Cells Mol Dis. 2007. PMID: 17532236 Review.

7

High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS.

Cario G, Izraeli S, Teichert A, Rhein P, Skokowa J, Möricke A, Zimmermann M, Schrauder A, Karawajew L, Ludwig WD, Welte K, Schünemann HJ, Schlegelberger B, Schrappe M, Stanulla M. Cario G, et al. Among authors: moricke a. J Clin Oncol. 2007 Oct 20;25(30):4813-20. doi: 10.1200/JCO.2007.11.8166. J Clin Oncol. 2007. PMID: 17947730

8

Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.

Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A; ALL-REZ BFM Study Group. Borgmann A, et al. Among authors: moricke a. Eur J Cancer. 2008 Jan;44(2):257-68. doi: 10.1016/j.ejca.2007.09.019. Epub 2007 Nov 5. Eur J Cancer. 2008. PMID: 17981026

9

Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia.

Cario G, Fetz A, Bretscher C, Möricke A, Schrauder A, Stanulla M, Schrappe M. Cario G, et al. Among authors: moricke a. Ann Hematol. 2008 Sep;87(9):709-16. doi: 10.1007/s00277-008-0504-x. Epub 2008 Jun 3. Ann Hematol. 2008. PMID: 18521602

10

Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.

Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA. Attarbaschi A, et al. Among authors: moricke a. J Clin Oncol. 2008 Jun 20;26(18):3046-50. doi: 10.1200/JCO.2008.16.1117. J Clin Oncol. 2008. PMID: 18565891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

111 results

Search Page

Filters